BACKGROUND: Only a fraction of circulating insulin-like activity is due to insulin itself. The aim of this study was to determine total serum insulin-like activity mediated via the insulin receptor isoform A (IR-A) and isoform B (IR-B) by using kinase receptor activation (KIRA) assays specific for the IR-A and IR-B. METHODS: The IR-A and IR-B KIRA assays use human embryonic kidney cells which have been transfected with the human IR-A or IR-B gene and quantify serum-mediated phosphorylation of the IR. RESULTS: Both IR KIRA assays were sensitive (detection limit 32 pmol/L) and precise (intra- and inter assay CV: <12% and <15%). The EC₅₀s of insulin, IGF-I and IGF-II were 1.4, 11.2 and 6.7 nmol/L for the IR-A KIRA assay, and 1.3, 31.0 and 15.7 nmol/L for the IR-B KIRA assay. The operational range of both assays allowed for determination of total insulin-like activity in human serum. Analysis of serum samples showed that there was a significant positive correlation between serum insulin-like and immunoreactive insulin concentrations (IR-A: r = 0.56, p = 0.01, IR-B: r = 0.68, p = 0.001). Importantly, addition of IGF-I or IGF-II antibodies to human serum samples could substantially decrease the endpoint signal in both KIRA assays. CONCLUSIONS: We showed that serum IGF-I and IGF-II may substantially contribute to IR signalling. Since IR isoform specific KIRA assays also take into account the contribution of IGFs present in serum on IR signalling, they may help to gain more insight into the roles of IGF mediated IR-A and IR-B activation in health and disease.
BACKGROUND: Only a fraction of circulating insulin-like activity is due to insulin itself. The aim of this study was to determine total serum insulin-like activity mediated via the insulin receptor isoform A (IR-A) and isoform B (IR-B) by using kinase receptor activation (KIRA) assays specific for the IR-A and IR-B. METHODS: The IR-A and IR-B KIRA assays use humanembryonic kidney cells which have been transfected with the humanIR-A or IR-B gene and quantify serum-mediated phosphorylation of the IR. RESULTS: Both IR KIRA assays were sensitive (detection limit 32 pmol/L) and precise (intra- and inter assay CV: <12% and <15%). The EC₅₀s of insulin, IGF-I and IGF-II were 1.4, 11.2 and 6.7 nmol/L for the IR-A KIRA assay, and 1.3, 31.0 and 15.7 nmol/L for the IR-B KIRA assay. The operational range of both assays allowed for determination of total insulin-like activity in human serum. Analysis of serum samples showed that there was a significant positive correlation between serum insulin-like and immunoreactive insulin concentrations (IR-A: r = 0.56, p = 0.01, IR-B: r = 0.68, p = 0.001). Importantly, addition of IGF-I or IGF-II antibodies to human serum samples could substantially decrease the endpoint signal in both KIRA assays. CONCLUSIONS: We showed that serum IGF-I and IGF-II may substantially contribute to IR signalling. Since IR isoform specific KIRA assays also take into account the contribution of IGFs present in serum on IR signalling, they may help to gain more insight into the roles of IGF mediated IR-A and IR-B activation in health and disease.
Authors: Peter M van Koetsveld; Giovanni Vitale; Wouter W de Herder; Richard A Feelders; Katy van der Wansem; Marlijn Waaijers; Casper H J van Eijck; Ernst-Jan M Speel; Ed Croze; Aart-Jan van der Lely; Steven W J Lamberts; Leo J Hofland Journal: J Clin Endocrinol Metab Date: 2006-08-15 Impact factor: 5.958
Authors: F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri Journal: Mol Cell Biol Date: 1999-05 Impact factor: 4.272
Authors: Giovanni Vitale; Peter M van Koetsveld; Wouter W de Herder; Katy van der Wansem; Joop A M J L Janssen; Annamaria Colao; Gaetano Lombardi; Steven W J Lamberts; Leo J Hofland Journal: Am J Physiol Endocrinol Metab Date: 2009-01-13 Impact factor: 4.310
Authors: Michael P Brugts; Michael B Ranke; Leo J Hofland; Katy van der Wansem; Karin Weber; Jan Frystyk; Steven W J Lamberts; Joseph A M J L Janssen Journal: J Clin Endocrinol Metab Date: 2008-04-08 Impact factor: 5.958
Authors: Stephanie Booy; Casper Hj van Eijck; Joseph Amjl Janssen; Fadime Dogan; Peter M van Koetsveld; Leo J Hofland Journal: Am J Cancer Res Date: 2015-05-15 Impact factor: 6.166
Authors: Aimee J Varewijck; Hannele Yki-Järvinen; Ronald Schmidt; Norbert Tennagels; Joseph A M J L Janssen Journal: Diabetes Date: 2013-04-08 Impact factor: 9.461
Authors: Joseph A M J L Janssen; Leo J Hofland; Christian J Strasburger; Elisabeth S R van den Dungen; Mario Thevis Journal: PLoS One Date: 2016-03-18 Impact factor: 3.240